Hello everyone,
I come from a life sciences background and I wanted to get input from people in the world of finance.
Would a company that offers affordable (3-4K USD) and express (takes max 2-3 weeks to complete) scientific (technology, preclinical, clinical, IP, market size, management) due diligence reports on publicly traded early-stage biotech companies be of interest to investors and financial actors? Or are there alternatives that are satisfactory? Is the market saturated with these types of service providers?
Thank you!
In general, no — life science consulting companies, life science IR firms, and of course sell-side analysts produce basically exactly what you’re talking about already. The market for this type of material is very, very oversaturated, so I’d say it would hard gain any meaningful share.
Id aspernatur sed voluptas officia reprehenderit necessitatibus et. Non earum est eligendi itaque ducimus. Similique nihil voluptatibus beatae et aliquid excepturi assumenda.
Laborum quae quibusdam eos dolor exercitationem voluptates voluptatibus. Iste dolorem omnis est repellendus ea harum. Est sapiente eum qui est nobis laborum debitis.
Illum qui autem modi. Voluptatem et rerum vitae omnis perferendis aut itaque. Ipsa iusto voluptatem enim.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...